{"id":18342,"date":"2015-12-30T11:38:45","date_gmt":"2015-12-30T10:38:45","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=18342"},"modified":"2015-12-30T11:38:45","modified_gmt":"2015-12-30T10:38:45","slug":"seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","title":{"rendered":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria"},"content":{"rendered":"<figure id=\"attachment_18345\" aria-describedby=\"caption-attachment-18345\" style=\"width: 298px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-1.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\" wp-image-18345 \" alt=\"curs-pacient-diabetic-tipusII (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-1.jpg\" width=\"298\" height=\"199\" \/><\/a><figcaption id=\"caption-attachment-18345\" class=\"wp-caption-text\">El doctor Pere Trav\u00e9 va ser un dels docents del curs que va acollir el COFB<\/figcaption><\/figure>\n<p>Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la diabetis mellitus tipus 2 (DM2). <b>Establir un bon control i seguiment del pacient diab\u00e8tic millora l\u2019adher\u00e8ncia al tractament, el grau de compliment de la ter\u00e0pia diet\u00e8tica o la resoluci\u00f3 dels problemes que presenta en general el programa terap\u00e8utic<\/b>, alhora que facilita el control glucometab\u00f2lic, la reducci\u00f3 de l&#8217;aparici\u00f3 de manifestacions agudes i cr\u00f2niques o atenua l&#8217;impacte si ja han aparegut.<\/p>\n<p>Amb l\u2019objectiu de formar i responsabilitzar al farmac\u00e8utic en les tasques de prevenci\u00f3, seguiment farmacoterap\u00e8utic i control del pacient amb aquesta malaltia, el COFB va acollir al mes de novembre el <strong>curs \u201cSeguiment del pacient diab\u00e8tic tipus II\u201d<\/strong>. La formaci\u00f3 va permetre establir mecanismes de coordinaci\u00f3 amb els equips d\u2019atenci\u00f3 prim\u00e0ria; tamb\u00e9 donar a con\u00e8ixer les estrat\u00e8gies diet\u00e8tiques que poden ajudar el pacient diab\u00e8tic a aconseguir canvis en els h\u00e0bits d&#8217;alimentaci\u00f3 i activitat f\u00edsica que aconsegueixin millorar el control metab\u00f2lic, permetent que els farmac\u00e8utics assistents implementin aquests serveis professionals a la farm\u00e0cia comunit\u00e0ria. \u201cAquests serveis s\u2019orienten a la <b>prevenci\u00f3 de la malaltia, la detecci\u00f3 de possibles pacients de risc, la identificaci\u00f3 de pacients diab\u00e8tics mal controlats i el seguiment farmacoterap\u00e8utic personalitzat <\/b>del pacient diab\u00e8tic per facilitar-li l\u2019adher\u00e8ncia i la seguretat del tractament farmacol\u00f2gic per tal d\u2019evitar l\u2019aparici\u00f3 d\u2019efectes adversos indesitjables\u201d explica <b>Pere Trav\u00e9<\/b>, doctor en farm\u00e0cia i diplomat a l\u2019Institut Pasteur de Paris, especialista en an\u00e0lisis cl\u00edniques i bioqu\u00edmica cl\u00ednica, i un dels docents del curs.<\/p>\n<p>La formaci\u00f3 es va dur a terme mitjan\u00e7ant l\u2019abordatge d\u2019h\u00e0bits higi\u00e8nico-diet\u00e8tics que impliquen la implementaci\u00f3 de programes de p\u00e8rdua de pes i plans d\u2019exercici f\u00edsic que condueixin a disminuir el risc de la malaltia. \u201cTanmateix, s\u2019han desenvolupat eines per a la detecci\u00f3 preco\u00e7 de la malaltia, donat que <strong>s\u2019estima que per cada pacient diab\u00e8tic conegut, existeix un altre que ho desconeix<\/strong> i que la seva freq\u00fc\u00e8ncia augmenta significativament amb l\u2019edat, l\u2019exc\u00e9s de pes i vida sedent\u00e0ria\u201d explica Trav\u00e9, i per abordar el problema \u201cs\u2019ha destinat un temps d\u2019aprenentatge per a promoure el cribratge en la poblaci\u00f3 susceptible de risc, segons les recomanacions del Ministeri de Sanitat\u201d.<\/p>\n<figure id=\"attachment_18347\" aria-describedby=\"caption-attachment-18347\" style=\"width: 572px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-3.jpg\"><img decoding=\"async\" class=\" wp-image-18347   \" alt=\"curs-pacient-diabetic-tipusII (3)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-3.jpg\" width=\"572\" height=\"349\" \/><\/a><figcaption id=\"caption-attachment-18347\" class=\"wp-caption-text\">Assistents al curs de seguiment del pacient diab\u00e8tic tipus II<\/figcaption><\/figure>\n<p>D\u2019altra banda, i <strong>donat que el pacient diab\u00e8tic presenta un alt risc cardiovascular i que aquest pot ser identificat a la farm\u00e0cia, es van dur a terme exercicis a l\u2019aula de c\u00e0lcul del risc coronari<\/strong> segons les <a href=\"http:\/\/www.regicor.org\/presentacio\/que-es\/framingham-regicor.html\" target=\"_blank\" rel=\"noopener\">taules Regicor<\/a>, adaptades a la poblaci\u00f3 catalana i amb les <a href=\"http:\/\/www.escardio.org\/Guidelines-&amp;-Education\/Practice-tools\/CVD-prevention-toolbox\/SCORE-Risk-Charts\" target=\"_blank\" rel=\"noopener\">taules Score de risc cardiovascular<\/a>, adaptades a la poblaci\u00f3 europea, per tal que els farmac\u00e8utics assistents adquirissin les compet\u00e8ncies necess\u00e0ries per a dur a terme aquest servei.<\/p>\n<p>Donada la import\u00e0ncia de portar un control des de la farm\u00e0cia dels pacients que pateixen aquesta malaltia -la diabetis \u00e9s una de les principals causes d\u2019insufici\u00e8ncia renal i els pacients diab\u00e8tics requeririen un control farmac\u00e8utic dels seus medicaments alhora que tamb\u00e9 cal tenir present les possibles complicacions que aquesta malaltia pot causar-, es va considerar d\u2019inter\u00e8s aprofundir en els sistemes per a la millora de l\u2019\u00fas efectiu i segur dels medicaments que utilitzen: \u201cConcretament, al curs es va treballar el m\u00e8tode de determinaci\u00f3 de la funci\u00f3 renal mitjan\u00e7ant el filtrat glomerular, accedint a la <a href=\"http:\/\/www.senefro.org\/modules.php?name=calcfg\" target=\"_blank\" rel=\"noopener\">p\u00e0gina web de la Societat Espanyola de Nefrologia (SEN)<\/a> per tal d\u2019entrenar el significat i \u00fas de les f\u00f3rmules, aix\u00ed com la categoritzaci\u00f3 de la malaltia renal\u201d matisa Trav\u00e9. El <b>seguiment farmacoterap\u00e8utic dels pacients diab\u00e8tics a la farm\u00e0cia \u00e9s un servei farmac\u00e8utic d\u2019elevada import\u00e0ncia, <\/b>donat que aquests pacients necessiten un <b>control peri\u00f2dic de la seva medicaci\u00f3<\/b> per garantir que s\u2019utilitzen de forma segura en funci\u00f3 de la p\u00e8rdua de la funcionalitat renal.<\/p>\n<p>A banda del doctor Trav\u00e9, l\u2019equip docent va estar formar per <strong>Merc\u00e8 Mercad\u00e9<\/strong>, farmac\u00e8utica comunit\u00e0ria i membre del grup de treball d&#8217;atenci\u00f3 farmac\u00e8utica del COFB, i <strong>Gemma Trib\u00f3<\/strong>, \u00a0farmac\u00e8utica comunit\u00e0ria, diploma en Alimentaci\u00f3 i nutrici\u00f3 comunit\u00e0ria de l\u2019Escuela Nacional de Sanidad, professora associada d&#8217;estades de pr\u00e0ctiques tutelades de la Facultat de Farm\u00e0cia i professora del m\u00e0ster oficial de farm\u00e0cia assistencial de la UB. La coordinaci\u00f3 va anar a c\u00e0rrec de <strong>Merc\u00e8 Barau<\/strong>, vocal de la Junta de Govern del Col\u00b7legi.<\/p>\n<p><strong>Potser tamb\u00e9 t&#8217;interessa:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/les-farmacies-de-barcelona-realitzaran-proves-per-identificar-factors-de-risc-cardiovascular-a-10-anys\/\">Les farm\u00e0cies de Barcelona realitzaran proves per identificar factors de risc cardiovascular a 10 anys<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/14-de-novembre-dia-mundial-de-la-diabetis\/\">14 de novembre: Dia Mundial de la Diabetis<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/la-farmacia-comunitaria-aprofundeix-coneixements-en-el-pla-de-salut\/\">La farm\u00e0cia comunit\u00e0ria aprofundeix coneixements en el Pla de Salut<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/diabetis-com-es-poden-prevenir-o-reduir-les-complicacions\/\">Diabetis: com es poden prevenir o reduir les complicacions? (v\u00eddeo)<\/a>\u00a0(Blog)<\/li>\n<\/ul>\n<p align=\"right\"><b>Amb la col\u00b7laboraci\u00f3 de:<\/b><\/p>\n<p align=\"right\"><b><a href=\"http:\/\/www.roche.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"alignright size-full wp-image-13052\" alt=\"roche\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/04\/roche.jpg\" width=\"120\" height=\"62\" \/><\/a><\/b><\/p>\n<p align=\"right\"><em>\u00a0<\/em><em>\u00a0\u00a0<\/em><i><em><br \/>\n<\/em><\/i><\/p>\n<p align=\"right\"><em><a href=\"http:\/\/www.rapidcontrol.es\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright  wp-image-18365\" alt=\"rapid control\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/rapid-control.jpg\" width=\"190\" height=\"103\" \/><\/a>\u00a0\u00a0<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":18346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[197,2298,113,69],"class_list":["post-18342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-diabetis","tag-dm2","tag-farmacia-assistencial","tag-farmacia-comunitaria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-12-30T10:38:45+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria\",\"datePublished\":\"2015-12-30T10:38:45+00:00\",\"dateModified\":\"2015-12-30T10:38:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"},\"wordCount\":935,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"diabetis\",\"DM2\",\"farm\u00e0cia assistencial\",\"farm\u00e0cia comunit\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\",\"name\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-12-30T10:38:45+00:00\",\"dateModified\":\"2015-12-30T10:38:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","og_locale":"ca_ES","og_type":"article","og_title":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-12-30T10:38:45+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria","datePublished":"2015-12-30T10:38:45+00:00","dateModified":"2015-12-30T10:38:45+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"},"wordCount":935,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["diabetis","DM2","farm\u00e0cia assistencial","farm\u00e0cia comunit\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","name":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-12-30T10:38:45+00:00","dateModified":"2015-12-30T10:38:45+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/18342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=18342"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/18342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=18342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=18342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=18342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}